Dextromethorphan/Lidocaine

右美沙芬/利多卡因

Report date: 2026/02/13 10:40:11

Base Information

Drug NameDextromethorphan/Lidocaine
Drug Alias NameLidocaine/Dextromethorphan利多卡因/右美沙芬Dextromethorphan+Lidocaine右美沙芬+利多卡因利多卡因+右美沙芬 +[7] 
ClassificationSmall molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonistsSodium channels blockers
TargetsGlutamate [NMDA] receptorSodium channels
Therapy Area/IndicationsDepressive Disorder, MajorMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Dextromethorphan HydrobromideLidocaine
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEndo International Plc
China Registration ClassN/A

Develop Information

Active CompaniesCspc Ouyi Pharmaceutical Co Ltd
Inactive CompaniesEndo International Plc
Active IndicationsDepressive Disorder, Major
Inactive IndicationsMigraine Disorders

Other Information

ATC CodeN/A
Related LinksN/A